Improving predictability of IgE-high type 2 chronic sinusitis with nasal polyps in the biologic era.
Biologics
Biomarkers
Chronic Rhinosinusitis
Endotype
Immunoglobulin-E
Monoclonal antibodies
Therapeutics
Journal
Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
ISSN: 1916-0216
Titre abrégé: J Otolaryngol Head Neck Surg
Pays: England
ID NLM: 101479544
Informations de publication
Date de publication:
23 May 2022
23 May 2022
Historique:
received:
31
12
2021
accepted:
12
05
2022
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
26
5
2022
Statut:
epublish
Résumé
Chronic rhinosinusitis (CRS) is an inflammatory disease that may require biological therapy. Omalizumab is an anti-IgE biologic that was recently approved by the FDA and Health Canada for use in severe CRS with nasal polyps (CRSwNP) recalcitrant to intranasal corticosteroids. Dosing is based on weight and pre-treatment serum IgE, with elevated levels of the latter being an indication for biologic treatment according to EPOS and EUFOREA guidelines. The goal of this study was to identify variables that predict IgE-high type 2 inflammation and serve as indicators for biologic treatment in CRS. Patients ≥ 19 yo diagnosed with CRS undergoing functional endoscopic sinus surgery were included retrospectively. Demographics, past medical history, preoperative blood work, Lund-Mackay (LM), Lund Kennedy (LK), and SNOT-22 scores were extracted. Descriptive statistics and binary logistic regression analyses were conducted. Model superiority was based on Nagelkerke R2 scores and receiver operating characteristic curves. Sixty-five patients, average age 49.96 ± 13.59 years, were included. Sixty-one binary logistic regression models for elevated serum IgE were created. Among the top 3 models, the best model had sensitivity, specificity, positive predictive value and negative predictive values of 82.1, 69.2, 80.0, and 72.0. All performance measures except sensitivity exceeded the Canadian Biologics Guideline model. Serum eosinophils ≥ 300 cell/uL, CRSwNP and LM ≥ 17 increased the odds of elevated IgE. IgE-high type-2 inflammation can be predicted by a model that includes eosinophil ≥ 300 cell/uL, CRSwNP, LM ≥ 17, asthma diagnosis and SNOT-22 ≥ 40. Patients meeting these parameters have a high pretest probability for elevated IgE and would benefit from IgE serology to determine qualification for omalizumab. This could reduce unwarranted IgE serology in patients with CRSwNP but also target a patient population for further workup that will lead to optimization of resource allocation and improve healthcare equity in rural and remote areas within Canada.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic rhinosinusitis (CRS) is an inflammatory disease that may require biological therapy. Omalizumab is an anti-IgE biologic that was recently approved by the FDA and Health Canada for use in severe CRS with nasal polyps (CRSwNP) recalcitrant to intranasal corticosteroids. Dosing is based on weight and pre-treatment serum IgE, with elevated levels of the latter being an indication for biologic treatment according to EPOS and EUFOREA guidelines. The goal of this study was to identify variables that predict IgE-high type 2 inflammation and serve as indicators for biologic treatment in CRS.
METHODS
METHODS
Patients ≥ 19 yo diagnosed with CRS undergoing functional endoscopic sinus surgery were included retrospectively. Demographics, past medical history, preoperative blood work, Lund-Mackay (LM), Lund Kennedy (LK), and SNOT-22 scores were extracted. Descriptive statistics and binary logistic regression analyses were conducted. Model superiority was based on Nagelkerke R2 scores and receiver operating characteristic curves.
RESULTS
RESULTS
Sixty-five patients, average age 49.96 ± 13.59 years, were included. Sixty-one binary logistic regression models for elevated serum IgE were created. Among the top 3 models, the best model had sensitivity, specificity, positive predictive value and negative predictive values of 82.1, 69.2, 80.0, and 72.0. All performance measures except sensitivity exceeded the Canadian Biologics Guideline model. Serum eosinophils ≥ 300 cell/uL, CRSwNP and LM ≥ 17 increased the odds of elevated IgE.
CONCLUSIONS
CONCLUSIONS
IgE-high type-2 inflammation can be predicted by a model that includes eosinophil ≥ 300 cell/uL, CRSwNP, LM ≥ 17, asthma diagnosis and SNOT-22 ≥ 40. Patients meeting these parameters have a high pretest probability for elevated IgE and would benefit from IgE serology to determine qualification for omalizumab. This could reduce unwarranted IgE serology in patients with CRSwNP but also target a patient population for further workup that will lead to optimization of resource allocation and improve healthcare equity in rural and remote areas within Canada.
Identifiants
pubmed: 35606866
doi: 10.1186/s40463-022-00580-y
pii: 10.1186/s40463-022-00580-y
pmc: PMC9128111
doi:
Substances chimiques
Biological Products
0
Omalizumab
2P471X1Z11
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22Informations de copyright
© 2022. The Author(s).
Références
Annu Rev Pathol. 2017 Jan 24;12:331-357
pubmed: 27959637
JAMA Intern Med. 2018 Jan 1;178(1):39-47
pubmed: 29131899
Laryngoscope. 2003 Jul;113(7):1199-205
pubmed: 12838019
J Allergy Clin Immunol. 2016 Nov;138(5):1344-1353
pubmed: 27544740
N Engl J Med. 2014 Sep 25;371(13):1198-207
pubmed: 25199059
Int Forum Allergy Rhinol. 2015 Aug;5(8):674-81
pubmed: 25952937
Clin Otolaryngol. 2019 Nov;44(6):887-897
pubmed: 31580530
J Allergy Clin Immunol. 2017 Feb;139(2):699-703.e7
pubmed: 27639939
J Allergy Clin Immunol. 2013 Jan;131(1):110-6.e1
pubmed: 23021878
Allergy. 2017 Apr;72(4):519-533
pubmed: 27861988
J Clin Epidemiol. 1996 Dec;49(12):1373-9
pubmed: 8970487
Indian J Otolaryngol Head Neck Surg. 2019 Nov;71(Suppl 3):1787-1792
pubmed: 31763246
J Allergy Clin Immunol. 2020 Sep;146(3):595-605
pubmed: 32524991
Allergy. 2021 Aug;76(8):2337-2353
pubmed: 33683704
Can Fam Physician. 2013 Dec;59(12):1275-81, e528-34
pubmed: 24336538
Am J Rhinol Allergy. 2016 Mar-Apr;30(2):134-9
pubmed: 26980394
Curr Opin Allergy Clin Immunol. 2015 Feb;15(1):1-13
pubmed: 25479315
World Allergy Organ J. 2020 Jan 06;13(1):100094
pubmed: 32015784
Rhinology. 2010 Sep;48(3):318-24
pubmed: 21038023
Rhinology. 2020 Feb 20;58(Suppl S29):1-464
pubmed: 32077450
Rhinology. 2021 Apr 1;59(2):151-163
pubmed: 33459728
Am J Rhinol Allergy. 2021 May;35(3):399-407
pubmed: 32967430
Diagnosis (Berl). 2017 Jun 27;4(2):79-86
pubmed: 29536919
Am J Rhinol Allergy. 2021 Jul;35(4):516-524
pubmed: 33153272
J Allergy Clin Immunol Pract. 2019 Nov - Dec;7(8):2812-2820.e3
pubmed: 31128376
J Allergy Clin Immunol. 2013 May;131(5):1350-60
pubmed: 23541327
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420950851
pubmed: 32816558
Drug Des Devel Ther. 2020 Dec 10;14:5483-5494
pubmed: 33328726
Allergy. 2019 Dec;74(12):2312-2319
pubmed: 31090937
Otolaryngol Head Neck Surg. 2007 Oct;137(4):555-61
pubmed: 17903570
J Allergy Clin Immunol. 2006 Nov;118(5):1133-41
pubmed: 17088140
J Allergy Clin Immunol. 2021 Jan;147(1):29-36
pubmed: 33227318
Rhinology. 2018 Sep 1;56(3):216-226
pubmed: 29785413
Am J Rhinol Allergy. 2021 Mar;35(2):256-263
pubmed: 32819148
Clin Rev Allergy Immunol. 2019 Apr;56(2):219-233
pubmed: 30206782
Clin Exp Allergy. 2020 May;50(5):585-596
pubmed: 32053269
Otolaryngol Head Neck Surg. 2015 Apr;152(2 Suppl):S1-S39
pubmed: 25832968
Int Forum Allergy Rhinol. 2020 Jun;10(6):755-761
pubmed: 32216166
Laryngoscope. 2022 May;132(5):933-941
pubmed: 34437720
J Otolaryngol Head Neck Surg. 2021 Mar 9;50(1):15
pubmed: 33750471
Clin Exp Allergy. 2014;44(5):690-700
pubmed: 24597471
JAMA. 2016 Feb 2;315(5):469-79
pubmed: 26836729
Int Forum Allergy Rhinol. 2017 Jun;7(6):591-599
pubmed: 28272838
J Allergy Clin Immunol. 2017 Mar;139(3):1061-1064.e4
pubmed: 27871878
J Allergy Clin Immunol. 2020 Aug;146(2):337-343.e6
pubmed: 32417132